Minakem-flap
Minakem-flap

Find Ophthalmology Drugs in Phase I/II Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BS01

            Therapeutic Area: Ophthalmology Product Name: BS01

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 30, 2021

            Details:

            The patients began reporting observations about their perceptions 2-3 months after BS01 was injected, and then were tested objectively and quantitatively at a testing site at 3 month and 6 month time points.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Retinal pigment epithelial cells

            Therapeutic Area: Ophthalmology Product Name: OpRegen

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 23, 2021

            Details:

            OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EXN407

            Therapeutic Area: Ophthalmology Product Name: EXN407

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Johnson & Johnson

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 02, 2021

            Details:

            In collaboration with Janssen Pharmaceuticals, the first patient has been dosed with Exonate's, EXN 407, in a Phase Ib/II clinical trial of patient volunteers with centre-involved diabetic macular oedema.